Лечение бисфосфонатами и патология пищевода
Аннотация
Обсуждается проблема побочных эффектов при использовании бисфосфонатов. Отмечено, что существенное значение для реальной клинической практики имеют осложнения со стороны желудочно-кишечного тракта, которые наблюдаются у 20-30% пациентов и являются основной причиной отказа от лечения. Этот аспект переносимости бисфосфонатов тщательно изучается, поскольку, помимо неспецифических симптомов (диспепсия или гастралгия), некоторые представители этой лекарственной группы способны вызывать и весьма серьезные специфические осложнения - язвы пищевода. Значительно уменьшить риск подобных осложнений, по-видимому, помогут использование новых препаратов и лекарственных форм, а также тщательный учет факторов риска при их назначении, четкие инструкции по применению и своевременный контроль за состоянием больных.
Литература
1. <div><p>Parfitt J., Driman D. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007; 38: 527-36.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009; 167 с.</p><p>Yeomans N., Lanas A., Labenz J. et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103(10): 2465-73.</p><p>Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ, 2003; 10-53.</p><p>Торопцова Н.В. Остеопороз: роль алендроната в лечении и профилактике заболевания. Consilium medicum 2008; 10(5): 12-7.</p><p>Bock O. Bisphosphonates in the management of postmenopausal osteoporosis - optimizing of efficacy in clinical practice. Clin Interven Aging 2008; 3(2): 279-97.</p><p>Iwamoto J., Takeda T., Sato Y. Efficacy and safety of alendronate and risedronate for post-menopausal osteoporosis. Curr Med Res Opin 2006; 22(5): 919-28.</p><p>Black D., Thompson D., Bauer D. et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. Fit research group. J Clin Endocrinol Metab 2000; 85: 4118-24.</p><p>Papapetrou P. Bisphosphonate-associated adverse events. Hormones 2009; 8(2): 96-110.</p><p>Higuchi D., Sugawa C., Shah S. et al. Etiology, treatment, and outcome of esophageal ulcers: a 10-year experience in an urban emergency hospital. Gastrointest Surg 2003; 7(7): 836-42.</p><p>Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002; 47(8): 1665-78.</p><p>Vаlean S., Petrescu M., Cаtinean A. et al. Pill esophagitis. Rom J Gastroenterol 2005; 14(2): 159-63.</p><p>Fernandes P., Pires M., Gouvеa A. Ulcerative esophagitis associated with the use of alendronate sodium: histopathological and endoscopic features. Arq Gastroenterol 2002; 39(3): 173-6.</p><p>Halkin H., Dushenat M., Silverman B. et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007; 41(1): 29-34.</p><p>Thomson A., Marshall J., Hunt R. et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29(9): 1965-74.</p><p>Thomson A., Appleman S., Keelan M. et al. Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa. Dig Dis Sci 2003; 48(2): 308-14.</p><p>Delmas P. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462-6.</p><p>Bone H., Hosking D., Devogelaer J. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350(12): 1189-99.</p><p>Bauer D., Black D., Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160(4): 517-25.</p><p>Greenspan S., Field-Munves E., Tonino R. et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77(10): 1044-52.</p><p>Cryer B., Binkley N., Simonelli C. et al. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother 2005; 3(3): 127-36.</p><p>Girelli C., Reguzzoni G., Rocca F. Alendronate-induced esophagitis. A report of 2 cases. Recenti Prog Med 1997; 88(5): 223-5.</p><p>Tоth E., Fork F., Lindelöw K. et al. Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports. Lakartidningen 1998; 95(35): 3676-80.</p><p>de Groen P., Lubbe D., Hirsch L. et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21.</p><p>Larsen K., Stray N., Engh V., Sandnes D. Esophageal lesions associated with diphospho- nates. Tidsskr Nor Laegeforen 2000; 120: 2397-9.</p><p>Luciani J., Pigatto V., Naves A. et al. Esophagitis associated with use of alendronate in 5 postmenopausic patients. Acta Gastroenterol Latinoam 2001; 31(2): 59-63.</p><p>Abid S., Mumtaz K., Jafri W. et al. Pill- induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37: 740-4.</p><p>Biswas P., Wilton L., Shakir S. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14: 507-14.</p><p>Lanza F., Hunt R., Thomson A. et al. Endoscopic Comparison of Esophageal and Gastroduodenal Effects of Risedronate and Alendronate in Postmenopausal Women. Gastroenterology 2000; 119: 631-8.</p><p>Vestergaard P., Schwartz K., Pinholt E. et al. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 2010; 86(2): 110-5.</p><p>Rizzoli R., Greenspan S., Bone G. et al. Two-year results of once-weekly administration of alendronate 70 mg for treatment of post-menopausal osteoporosis. J Bone Miner Res 2002; 17: 1988-96.</p><p>Reginster J., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.</p><p>Emkey R., Delmas P., Bolognese M. et al. Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study. Clin Ther 2009; 34(4): 751-61.</p><p>Lewiecki E., Babbitt A., Piziak V. et al. Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12- Month, Open-Label, Prospective Evaluation. Clin Ther 2008; 30(4): 605-21.</p></div><br />
Для цитирования:
Karateyev A.E. Лечение бисфосфонатами и патология пищевода. Современная ревматология. 2010;4(3):73-79. https://doi.org/10.14412/1996-7012-2010-625
For citation:
Karateyev A.E. BISPHOSPHONATE TREATMENT AND ESOPHAGEAL DISEASE. Modern Rheumatology Journal. 2010;4(3):73-79. (In Russ.) https://doi.org/10.14412/1996-7012-2010-625
Просмотров: 914
Послать статью по эл. почте 